Comparative study of the effectiveness of zuclopenthixol acetate and haloperidol in acutely disturbed psychotic patients

Journal of the Medical Association of Thailand

Volumn 85, Issue 12, 2002, Pages 1301-1308

  Taymeeyapradit, Unchulee ^a   Kuasirikul, Surachai ^b  

^a Songkla Neuropsychiatric Hospital   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Acute Psychosis; Aggression; Effectiveness; Haloperidol; Zuclopenthixol Acetate

Indexed keywords

HALOPERIDOL; NEUROLEPTIC AGENT; ZUCLOPENTHIXOL ACETATE; CLOPENTHIXOL;

ACUTE PSYCHOSIS; ADULT; AGED; AGGRESSION; ANTICHOLINERGIC EFFECT; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; INJECTION SITE; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SAMPLING; SEDATION; SIDE EFFECT; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; STUDENT T TEST; TREATMENT OUTCOME; TREMOR; ACUTE DISEASE; BRIEF PSYCHIATRIC RATING SCALE; DOSE RESPONSE; DRUG ADMINISTRATION; FOLLOW UP; HOSPITALIZATION; PROBABILITY; PSYCHOSIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; STATISTICAL MODEL;

ACUTE DISEASE; ADULT; BRIEF PSYCHIATRIC RATING SCALE; CLOPENTHIXOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HALOPERIDOL; HUMANS; LINEAR MODELS; MALE; PROBABILITY; PSYCHOTIC DISORDERS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0036988219     PISSN: 01252208     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. rd edit. Edited by Hales R, Yudofsky S, Talbott J. Washington DC: American Psychiatric Press, 1999: 1405-28.
2. Brizer D. Psyclopharmacology and the management of violent patients. Psychiatr Clin North Am 1988; 11: 551-68.
3. Chouinard G, Annable L, Tumier L, Holobow N, Szkrumelak N. A double-blind randomized clinical trial of rapid tranquilization with I.M. clonazepam and I.M. haloperidol in agitated psychotic patients with manic symptoms. Can J Psychiatry 1993; 38 (Suppl 4): S114-21.
4. Battaglia J, Moss S, Rush J, et al. Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective emergency, department study. Am J Emerg Med 1997; 15: 335-40.
5. Bieniek S, Ownby R, Penalver A, Dominguez R. A double-blind study of lorazepam versus the combination of haloperidol and lorazepam in managing agitation. Pharmacotherapy 1998; 18: 57-62.
6. Dorevitch A, Katz N, Zernishlany Z, Aizenberg D, Weizmen A. Intramuscular flunitrzepan versus intramuscular haloperidol in the emergency treatment of aggressive psychotic behavior. Am J Psychiatry 1999; 156: 142-4.
7. Norteved H, Hojelse F. Repeated intramuscular injections of zuclopenthixol acetate and haloperidol-local tolerance at injection site, in Symposium for Dutch Psychiatrists. Copenhagen, Denmark, 1989: 3-10.
8. Svendsen O, Hojelse F, Bagdon RE. Tests for local toxicity of intramuscular drug preparations: Comparison of in vivo and in vitro methods. Acta Pharmacol Toxicol (Copenh) 1985; 56: 183-90.
9. Amdisen A, Aaes-Jorgensen T, Thomsen NJ, Madsen VT, Nielsen MS. Serum concentrations and clinical effect of zuclopenthixol in acutely disturbed, psychotic patients treated with zuclopenthixol acetate in Viscoleo. Psychopharmacology 1986; 90: 412-6.
10. Balant LP, Balant-Gorgia AE, Eisele R, Reith B, Gex-Fabry M, Garrone G. Clinical and pharmacokinetic evaluation of zuclopenthixol acetate in Viscoleo. Pharmacopsychiatry 1989; 22: 250-4.
11. Chouinard G, Safadi G, Beauclair L. A double-blind controlled study of intramuscular zuclopenthixol acetate and liquid oral haloperidol in the treatment of schizophrenic patients with acute exacerbation. J Clin Psychopharmacol 1994; 14: 377-84.
12. Matar AM, Abdel-Mawgoud M, Skov S. Zuclopenthixol: A new generation of antipsychotic drugs. An open clinical trial. J Clin Psychopharmacol 1990; 10: 283-6.
13. Amdisen A, Nielsen MS, Dencker SJ, et al. Zuclopenthixol acetate in Viscoleo-a new drug formulation. An open Nordic multicentre study of zuclopenthixol acetate in Viscoleo in patients with acute psychoses including mania and exacerbation of chronic psychoses. Acta Psychiatr Scand 1987; 75: 99-107.
14. Baastrup PC, Alhfors UG, Bjerkenstedt L, et al. A controlled Nordic multicentre study of zuclopenthixol acetate in oil solution, haloperidol and zuclopenthixol in the treatment of acute psychosis. Acta Psychiatr Scand 1993; 87: 48-58.
15. Keikkila L, Eliander H, Vartiainen H, Turunen M, Pedersen V. Zuclopenthixol and haloperidol in patients with acute psychotic states. A double-blind, mult-centre study. Curr Med Res Opin 1992; 12: 594-603.
16. Tan CH, Low BL, Ng LL, Khoo YM, Lee HS. Clinical evaluation and serum concentration of zuclopenthixol acetate in psychotic Asian patients: A single-dose preliminary study. Ther Drug Monit 1993; 15: 108-12.
17. Chakravarti SK, Muthu A, Muthu PK, Naik P, Pinto RT. Zuclopenthixol acetate (5% in 'Viscoleo'): Single-dose treatment for acutely disturbed psychotic patients. Curr Med Res Opin 1990; 12: 5865.
18. Lowert AC, Rasmussen EM, Holm R, et al. Acute psychotic disorders treated with 5% zuclopenthixol acetate in 'Viscoleo' ('Cisordinol-Acutard'), a global assessment of the clinical effect: An open multicentre study. Pharmatherapeutica 1989; 5: 380-6.
19. Overall J, Gorham D. The brief psychiatric rating scale. Psycol Rep 1962; 10: 799-812.
20. Laurier C, Kennedy W, Lachaine J, Gariepy L, Tessier G. Economic evaluation of zuclopenthixol acetate compared with injectable haloperidol in schizophrenic patients with acute psychosis. Clin Ther 1997; 19: 316-29.
21. Fitzgerald P. Long-acting antipsychotic medication, restraint and treatment in the management of acute psychosis. Aust N Z J Psychiatry 1999; 33: 660-6.